Apogee’s Royalty Deal With Blackstone Will Fund Pivotal Test in Eczema and More
Blackstone Life Sciences is providing Apogee Therapeutics with up to $1.3 billion in non-dilutive financing, which the biotech will apply to a key test of its lead drug candidate in atopic dermatitis. The long-acting antibody also has potential applications in asthma and eosinophilic esophagitis.